GlobeNewsWire
01 Jun 2026, 23:30 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
The South Korean Ministry of Food and Drug Safety (MFDS) granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for Duchenne muscular dystrophy. — These designations reduce regulatory hurdles and accelerate the timeline for market entry in a key Asian geography.
+0.60Nxera Pharma plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026. — Provides a concrete timeline for potential commercialization and revenue generation in the Korean market.
+0.40The GIFT designation allows for a shortened review timeline of up to 90 working days compared to the standard 120 days. — Faster approval cycles reduce the time-to-market and associated capital burn for the company.
+0.30Ticker attribution
Continue reading
6 related stories
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Browse live screeningsImpact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
8h ago
